Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin

What Was Tested

This registered phase 4 trial tested Liraglutide for pcos.

The researchers anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with liraglutide or metformin.

It had three arms (groups): metformin (active comparator), liraglutide (active comparator) and metformin and liraglutide (active comparator).

The registry classes the interventions as drug.

Who Took Part

36 actual participants took part.

It was open to women only aged from 18 years up to 55 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: 18 years old to menopause. Polycystic ovary syndrome (NICHD criteria). BMI of 30 kg/m² or higher. Poor response to previous treatment with metformin for at least 3 months.

The full record lists 4 inclusion and 7 exclusion criteria; among the exclusions: type 1 or type 2 diabetes mellitus; history of carcinoma; cushing's syndrome or congenital (non-classic) adrenal hyperplasia.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the pcos participants stayed in one arm throughout.

Everyone knew when Liraglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2011-11 with completion listed for 2012-10.

It ran at 1 site in Slovenia.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: The main outcome was change in body weight (time frame: Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial).

It also tracked 2 secondary outcomes, for example The secondary outcome was change in body mass index (BMI) and The secondary outcome was change in waist circumference.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Liraglutide in 36 people with pcos.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Liraglutide compound page, PCOS research.